ATE341341T1 - Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs - Google Patents

Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs

Info

Publication number
ATE341341T1
ATE341341T1 AT00950930T AT00950930T ATE341341T1 AT E341341 T1 ATE341341 T1 AT E341341T1 AT 00950930 T AT00950930 T AT 00950930T AT 00950930 T AT00950930 T AT 00950930T AT E341341 T1 ATE341341 T1 AT E341341T1
Authority
AT
Austria
Prior art keywords
treating
pharmaceutical formulation
colorectal cancer
kinase inhibitors
formulation containing
Prior art date
Application number
AT00950930T
Other languages
English (en)
Inventor
Philip Frost
Carolyn Mary Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE341341T1 publication Critical patent/ATE341341T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00950930T 1999-08-12 2000-08-02 Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs ATE341341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
ATE341341T1 true ATE341341T1 (de) 2006-10-15

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950930T ATE341341T1 (de) 1999-08-12 2000-08-02 Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs

Country Status (24)

Country Link
EP (1) EP1202746B1 (de)
JP (1) JP2003507342A (de)
KR (1) KR20020018201A (de)
CN (1) CN1229142C (de)
AR (1) AR029763A1 (de)
AT (1) ATE341341T1 (de)
AU (1) AU783116B2 (de)
BR (1) BR0013219A (de)
CA (1) CA2380904C (de)
CZ (1) CZ2002474A3 (de)
DE (1) DE60031127T2 (de)
DK (1) DK1202746T3 (de)
EA (1) EA006876B1 (de)
ES (1) ES2272305T3 (de)
HK (1) HK1042244A1 (de)
HU (1) HUP0203162A3 (de)
IL (1) IL147913A0 (de)
MX (1) MXPA02001448A (de)
NO (1) NO20020663L (de)
NZ (1) NZ517120A (de)
PL (1) PL353267A1 (de)
PT (1) PT1202746E (de)
WO (1) WO2001012227A1 (de)
ZA (1) ZA200201156B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
IL151249A0 (en) * 2000-03-13 2003-04-10 American Cyanamid Co Use of cyanoquinolines for treating or inhibiting colonic polyps
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1412367A4 (de) 2001-06-21 2006-05-03 Ariad Pharma Inc Neue chinoline und deren verwendung
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ATE360015T1 (de) 2002-07-31 2007-05-15 Critical Outcome Technologies Protein tyrosin kinase inhibitoren
ATE380810T1 (de) 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine-kinase-inhibitoren
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
HRP20090495T1 (hr) 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
AP2204A (en) 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP2283020B8 (de) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituierte imidazopyr- und imidazotriazine
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340753A1 (en) * 1997-11-04 2001-02-26 Pfizer Prod Inc Substitution of indazolic bioisoster for cathechol in therapeutically active compounds
NZ503991A (en) * 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Also Published As

Publication number Publication date
DE60031127T2 (de) 2007-02-01
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
NZ517120A (en) 2004-10-29
DK1202746T3 (da) 2007-01-02
EA006876B1 (ru) 2006-04-28
CA2380904C (en) 2009-02-10
CN1229142C (zh) 2005-11-30
PT1202746E (pt) 2007-01-31
HUP0203162A3 (en) 2006-07-28
EP1202746A1 (de) 2002-05-08
EA200200246A1 (ru) 2002-08-29
BR0013219A (pt) 2002-04-23
CZ2002474A3 (cs) 2003-02-12
ZA200201156B (en) 2003-05-12
AU6395900A (en) 2001-03-13
EP1202746B1 (de) 2006-10-04
DE60031127D1 (de) 2006-11-16
WO2001012227A1 (en) 2001-02-22
NO20020663D0 (no) 2002-02-11
CN1370080A (zh) 2002-09-18
ES2272305T3 (es) 2007-05-01
MXPA02001448A (es) 2002-07-02
JP2003507342A (ja) 2003-02-25
KR20020018201A (ko) 2002-03-07
AR029763A1 (es) 2003-07-16
NO20020663L (no) 2002-04-09
HK1042244A1 (zh) 2002-08-09
IL147913A0 (en) 2002-08-14
HUP0203162A2 (hu) 2003-01-28
PL353267A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
DE60031127D1 (de) Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
ATE322266T1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60036879D1 (de) Indazol-verbindungen und pharmazeutische zusammensetzungen zur hemmung von proteinkinasen und verfahren zu ihrer verwendung
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
NO20002166L (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE60211913D1 (de) Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
NO20005680D0 (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
DE69911582D1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
DE602004003829D1 (de) 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
DE502004008837D1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
ATE288279T1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
EP1216051A4 (de) Anti-krebs medikament und methode zur krebsbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1202746

Country of ref document: EP

REN Ceased due to non-payment of the annual fee